MY184858A - Substituted pyridopyrimidine compounds and their use as flt3 inhibitors - Google Patents
Substituted pyridopyrimidine compounds and their use as flt3 inhibitorsInfo
- Publication number
- MY184858A MY184858A MYPI2014702705A MYPI2014702705A MY184858A MY 184858 A MY184858 A MY 184858A MY PI2014702705 A MYPI2014702705 A MY PI2014702705A MY PI2014702705 A MYPI2014702705 A MY PI2014702705A MY 184858 A MY184858 A MY 184858A
- Authority
- MY
- Malaysia
- Prior art keywords
- flt3 inhibitors
- formula
- compounds
- substituted pyridopyrimidine
- pyridopyrimidine compounds
- Prior art date
Links
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000008518 pyridopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/032575 WO2013142382A1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY184858A true MY184858A (en) | 2021-04-27 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014702705A MY184858A (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (instruction) |
| EP (1) | EP2828259B1 (instruction) |
| JP (1) | JP6101341B2 (instruction) |
| KR (1) | KR102011770B1 (instruction) |
| CN (1) | CN104428298B (instruction) |
| AU (1) | AU2013235344B2 (instruction) |
| BR (1) | BR112014023460B1 (instruction) |
| CA (1) | CA2868156C (instruction) |
| CL (1) | CL2014002505A1 (instruction) |
| EA (1) | EA031267B1 (instruction) |
| ES (1) | ES2694223T3 (instruction) |
| IL (1) | IL234802B (instruction) |
| IN (1) | IN2014MN02082A (instruction) |
| MX (1) | MX360912B (instruction) |
| MY (1) | MY184858A (instruction) |
| NZ (1) | NZ700283A (instruction) |
| PL (1) | PL2828259T3 (instruction) |
| SG (1) | SG11201405942RA (instruction) |
| TR (1) | TR201816480T4 (instruction) |
| WO (1) | WO2013142382A1 (instruction) |
| ZA (1) | ZA201407588B (instruction) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056048T2 (hu) * | 2013-10-21 | 2022-01-28 | Genosco | Helyettesített pirimidin vegyületek és SYK inhibitorként való alkalmazásuk |
| JP6665154B2 (ja) * | 2014-07-17 | 2020-03-13 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換尿素誘導体及びその薬学的使用 |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR20170087913A (ko) * | 2014-11-17 | 2017-07-31 | 로드아일랜드하스피틀 | 나노물질, 조성물, 합성, 및 어셈블리 |
| US12350272B2 (en) * | 2018-06-27 | 2025-07-08 | Oscotec Inc. | Pyridopyrimidinone derivatives for use as AXL inhibitors |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0017075A (pt) * | 2000-01-27 | 2002-11-05 | Warner Lambert Co | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa |
| CA2420286A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| BR0113590A (pt) * | 2000-08-31 | 2003-07-22 | Hoffmann La Roche | 7-oxo-piridopirimidinas |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2010019637A1 (en) * | 2008-08-12 | 2010-02-18 | Smithkline Beecham Corporation | Chemical compounds |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| KR20120059558A (ko) * | 2009-08-19 | 2012-06-08 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 화합물 및 이의 사용 방법 |
| SG10201407012XA (en) * | 2009-10-29 | 2014-11-27 | Genosco | Kinase inhibitors |
-
2013
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en not_active Ceased
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active Active
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
-
2014
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130274274A1 (en) | 2013-10-17 |
| EP2828259B1 (en) | 2018-08-08 |
| ES2694223T3 (es) | 2018-12-19 |
| CA2868156C (en) | 2020-07-28 |
| JP6101341B2 (ja) | 2017-03-22 |
| EP2828259A1 (en) | 2015-01-28 |
| CN104428298A (zh) | 2015-03-18 |
| ZA201407588B (en) | 2015-11-25 |
| NZ700283A (en) | 2016-08-26 |
| IL234802B (en) | 2018-10-31 |
| MX360912B (es) | 2018-11-22 |
| AU2013235344B2 (en) | 2017-03-16 |
| SG11201405942RA (en) | 2014-10-30 |
| PL2828259T3 (pl) | 2019-02-28 |
| EA031267B1 (ru) | 2018-12-28 |
| KR102011770B1 (ko) | 2019-08-19 |
| BR112014023460B1 (pt) | 2020-09-01 |
| JP2015510942A (ja) | 2015-04-13 |
| CA2868156A1 (en) | 2013-09-26 |
| HK1208453A1 (en) | 2016-03-04 |
| TR201816480T4 (tr) | 2018-11-21 |
| EA201491747A1 (ru) | 2015-10-30 |
| KR20140144709A (ko) | 2014-12-19 |
| AU2013235344A1 (en) | 2014-10-09 |
| EP2828259A4 (en) | 2015-08-19 |
| WO2013142382A1 (en) | 2013-09-26 |
| CN104428298B (zh) | 2017-03-01 |
| IN2014MN02082A (instruction) | 2015-08-21 |
| US8877763B2 (en) | 2014-11-04 |
| CL2014002505A1 (es) | 2015-10-02 |
| MX2014011354A (es) | 2014-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| NZ700928A (en) | Dna-pk inhibitors | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX2014002683A (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX2013010839A (es) | Metodo para inhibir flt3 cinasa fosforilada constitutivamente activa. | |
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| IN2015DN01156A (instruction) | ||
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| MY184561A (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k | |
| EA201491878A8 (ru) | Замещенные ксантиновые производные | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |